Zobrazeno 1 - 10
of 11
pro vyhledávání: ''
Autor:
Shusei Fukunaga, Naoto Tamai, Taku Sakamoto, Yutaka Saito, Minori Matsumoto, Takeshi Nakajima, Tsuyoshi Kikuchi, Takahisa Matsuda
Publikováno v:
Japanese Journal of Clinical Oncology. 42:1028-1034
Objective: Endoscopic resection techniques for treating colorectal tumors have advanced re-cently so that large colorectal tumors can now be treated endoscopically, although somepatients experience delayed bleeding after endoscopic resection. Our aim
Publikováno v:
Japanese journal of clinical oncology. 46(3)
OBJECTIVE The aim of this study was to evaluate a diffusion-weighted magnetic resonance imaging to represent therapeutic response of induction chemoradiation and outcome in patients with non-small cell lung cancer of the superior sulcus. METHODS Seve
Autor:
Tohru Shiga, Kiyohiro Houkin, Hidefumi Aoyama, Kenji Hirata, Takuhito Narita, Shunsuke Terasaka, Junichi Murata, Shinya Tanaka, Hiroyuki Kobayashi, Shunsuke Onodera
Publikováno v:
Japanese Journal of Clinical Oncology. 42:120-123
Two glioblastoma multiforme patients underwent (18)F-FMISO (fluoromisonidazole) positron emission tomography study to access the tumor oxygenation status before and immediately after fractionated radiotherapy concomitant with temozolomide chemotherap
Autor:
Daisuke Tamura, Motoko Tachihara, Hiroshi Otera, Yasuhiro Funada, Yoshihiro Nishimura, Yumiko Ishikawa, Kazuyuki Kobayashi, Suya Hori
Publikováno v:
Japanese Journal of Clinical Oncology. 44:762-764
We report the case of a 70-year-old Japanese male diagnosed with advanced lung adenocarcinoma harboring the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene. As soon as crizotinib was administered, tumor shrank
Autor:
Shinya Minatoguchi, Masahiro Nakano, Junki Endo, Fumitaka Ito, Yasushi Ohno, Hidenori Mori, Komei Yanase, Norihiko Funaguchi, Bu Lin Bai La
Publikováno v:
Japanese Journal of Clinical Oncology. 40:263-266
We report a case of gefitinib-induced bilateral upper urinary tract bleeding in an 82-year-old woman administered the drug daily for advanced non-small cell adenocarcinoma of the lung (T4N3M0). Hematuria is an uncommon adverse effect of gefitinib, an
Autor:
Arb-Aroon Lertkhachonsuk, Chuenkamon Charakorn, Suwicha Chittithaworn, Puchong Likittanasombut, Duangmani Thanapprapasr, Sarikapan Wilailak, Nathpong Israngura Na Ayudhya, Sawaek Weerakiet
Publikováno v:
Japanese Journal of Clinical Oncology. 40:203-207
Objective: To evaluate the effectiveness of vaginal misoprostol in overcoming an unsatisfactory colposcopy in the patients who had abnormal cervical cytology and to evaluate side effects of vaginal misoprostol. Methods: Sixty patients with an unsatis
Publikováno v:
Japanese Journal of Clinical Oncology
Sunitinib is a small molecular inhibitor of tyrosine kinases and is used to treat advanced renal cell carcinoma and gastrointestinal stromal tumour after disease progression or intolerance to imatinib therapy. Here, we describe biochemical and pathol
Autor:
Satoru Iwasa, Makiko Ono, Chikako Shimizu, Masashi Ando, Eriko Nakano, Taizo Hirata, Noriyuki Katsumata, Mayu Yunokawa, Kan Yonemori, Yasuhiro Fujiwara, Tsutomu Kouno, Kenji Tamura
Publikováno v:
Japanese Journal of Clinical Oncology. 39:456-459
This case report details a relapse with malignant transformation after the completion of bleomycin, etoposide and cisplatin chemotherapy for primary mediastinal seminoma, although the residual mass after chemotherapy was
Publikováno v:
Japanese journal of clinical oncology. 45(4)
Recently, new drugs targeting the immune system have been introduced to the standard care of metastatic malignant melanoma. One of these immunomodulatory drugs is ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antige
Autor:
Makoto Tahara, Hironobu Minami, Yoshiki Kojima, Takashi Sato, Hirofumi Mukai, Kaoru Shimokata, Hiromichi Ebi, Kenji Kawada, Koji Murakami
Publikováno v:
Japanese Journal of Clinical Oncology. 37:44-48
Background: To evaluate the role of FDG-PET in assessing anti-tumor efficacy of molecular targeted drugs, we prospectively performed FDG-PET and CT for response evaluation in patients treated with lapatinib, a dual inhibitor of ErbB1 and ErbB2 tyrosi